1[1]Sacks FM, MA Pfeffer, Moye LA, et al. For the Cholesterol and Recurrent Events Trial Investigaors. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996; 335: 1001～ 1009
2[2]Robert S, Roserson MD, Christine C, et al. Antiatherothrombotic Properties of Statin. JAMA, 1998; 229:1643～1650
3[3]J Dupuis, JC Tardif, P Cernacak, et al. Cholesterol reduction rapidy improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischaemia and Function of the Endothelium) trial. Circulation, 1999; 99:3227～ 3233
4[4]Ridker PM, Rifai N, Pfeffer Ma, et al. For the Cholesterol and Recurrent Events (CARE)Investigatiors. Long-term effect of pravastatin on plasma concertration of C-reactive protein.Circulation, 1999; 100:230～235
5[5]Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation, 1995; 92:3172～3177
3Aliison Oler. Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients With Unstable Angina. JAMA, 1996, 276: 811-815.
10Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996;335(14): 1001～1009
